Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
[WEBINAR] Molecular bioanalysis considerations along the drug development journey 11 days 19 hours 17 mins 0 secs REGISTER NOW!

Poster: Comparative metabolomics analysis of prostate cancer cells with different ethnic and tumorigenic phenotypes (Waters Corporation)

7 Oct 2014
General interest

A comprehensive high-throughput lipidomics and metabolomics analysis of prostate cancer cells with different tumorigenic phenotypes reveal potential markers for aggressive disease.

Click here to view poster

Related Links

  • Waters Corporation

Top content

  • Waters launches the Xevo TQ Absolute XR at ASMS 2025
  • How can diagnostic laboratories accelerate the clinical adoption of allogeneic cell therapies?
  • Why NGS ELN deployments fail

Related tags

cancer high-throughput metabolomics
Previous article Next article

Related articles

28 MAR 2017 METABOLITES

5. With the increase in research into metabolites how can the field be regulated and standardized?

24 DEC 2013 CLINICAL

Study suggests blood test can accurately detect breast cancer

19 DEC 2013 MS (LC–MS/MS, HRMS, IMS)

Multiplatform approach important for metabolic fingerprinting

6 JUN 2013 CHROMATOGRAPHY

GC–MS urinary metabolic profiles show promise in diagnosis of autism spectrum disorder

14 FEB 2017 NEWS

Chromatography and Mass Spectrometry utilized to detect breast cancer earlier

20 FEB 2014 CHROMATOGRAPHY

Interview with Irving W Wainer (NIH) on his career so far and the future of bioanalysis

  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
Contact
Contact Us
Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone